anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study is a prospective, single center, postmarket study to evaluate the safety and effectiveness of NeoPatch used as a tissue cover for chronically injured tendons requiring surgical revision. NeoPatch is a tissue covering derived from terminally sterilized, dehydrated human placental membrane tissue comprised of both amnion and chorion. Candidates for this study are patients presenting with chronic tendon pain that are being evaluated for primary tendon revision surgery following failure of standard of care or immediate need for surgery, as determined by the investigator. Consented patients will receive NeoPatch as an adjunct to their foot or ankle tendon revision; NeoPatch will be wrapped around the tendon immediately prior to closure. The study will be divided into two phases: Screening and Follow-up. The study will include prospective patient evaluations at scheduled clinic visits and ultrasound appointments for a maximum of 12 visits over 12 months. Patient history, medications, self-reported pain, tendon status, and adverse events will be collected on all patients consented and enrolled into the study.
The study was originally designed to have two arms (GCSF first followed by placebo= Arm 1; placebo followed by GCSF=Arm2). Total length of study for each subject was 14 weeks, with crossover on week 7.

Linear regression models could not be used because of the small number of subjects; n = 5 in the first Arm who received G-CSF before crossover to the placebo phase and n = 3 in Arm 2 (who received placebo first before crossover to the G-CSF treatment phase). The general rule for the sample size required for regression analysis is n = 15 per covariate. Therefore, comparison of the final cognitive scores on visit 5 (week 14) were compared to scores at baseline (visit 1) for all subjects (n = 8) using the Wilcoxon signed rank test. Plasma cytokine changes were plotted to compare effects following G-CSF to that following placebo, regardless of the order of treatment. Wilcoxon sum rank test was used to test differences between G-CSF treatment and placebo treatment at specific intervals after treatment. Statistical Package for the Social Sciences (SPSS Version 19) was used for all data analysis.
Skyla contains 13.5 mg of levonorgestrel (LNG) released in vivo at a rate of approximately 14 mcg/day after 24 days. This rate decreases progressively to approximately 6 mcg/day after 1 year and to 5 mcg/day after 3 years. The average in vivo release rate of LNG is approximately 8 mcg/day over the first year of use and 6 mcg/day over a period of 3 years. [See Clinical Pharmacology (12.3).]

Skyla must be removed by the end of the third year and can be replaced at the time of removal with a new Skyla if continued contraceptive protection is desired. 

Skyla can be physically distinguished from other intrauterine systems (IUSs) by the combination of the visibility of the silver ring on ultrasound and the brown color of the removal threads.

Skyla is supplied in a sterile package within an inserter that enables single-handed loading (see Figure 1). Do not open the package until required for insertion [see Description (11.2)]. Do not use if the seal of the sterile package is broken or appears compromised. Use strict aseptic techniques throughout the insertion procedure [see Warnings and Precautions (5.3)].
Soon after the outbreak of coronavirus disease 2019 (COVID-19), unexplained sustained fatigue, cognitive disturbance, and muscle ache/weakness were reported in patients who had recovered from acute COVID-19 infection. This abnormal condition has been recognized as "long COVID (postacute sequelae of COVID-19 [PASC])" with a prevalence estimated to be from 10 to 20% of convalescent patients. Although the pathophysiology of PASC has been studied, the exact mechanism remains obscure. Microclots in circulation can represent one of the possible causes of PASC. Although hypercoagulability and thrombosis are critical mechanisms of acute COVID-19, recent studies have reported that thromboinflammation continues in some patients, even after the virus has cleared. Viral spike proteins and RNA can be detected months after patients have recovered, findings that may be responsible for persistent thromboinflammation and the development of microclots. Despite this theory, long-term results of anticoagulation, antiplatelet therapy, and vascular endothelial protection are inconsistent, and could not always show beneficial treatment effects. In summary, PASC reflects a heterogeneous condition, and microclots cannot explain all the presenting symptoms. After clarification of the pathomechanisms of each symptom, a symptom- or biomarker-based stratified approach should be considered for future studies.
OBJECTIVE: Local infiltration analgesia (LIA), adductor canal block (ACB), and infiltration between the popliteal artery and the capsule of the posterior knee (IPACK) are popular multimodal analgesia techniques used during total knee arthroplasty (TKA). This study aimed to explore the efficacy of adding the IPACK technique to ACB and LIA in patients undergoing TKA.
METHODS: In this retrospective cohort study, patients who underwent primary unilateral TKA were divided into two groups based on their date of admission. Sixty-three patients underwent IPACK, ACB and LIA (IPACK group) during surgery, while 60 patients underwent ACB and LIA (control group). The primary outcome was the postoperative administration of morphine hydrochloride as a rescue analgesic. Secondary outcomes included time to first rescue analgesia, postoperative pain assessed using the visual analog scale (VAS), functional recovery assessed by knee range of motion and ambulation distance, time until hospital discharge, and complication rates.
RESULTS: The two groups were similar in average postoperative 0-to-24-h morphine consumption (11.8 mg for the control group vs 12.7 mg for the IPACK group, p = .428) and average total morphine consumption (18.2 mg vs 18.0 mg, p = .983) during hospitalization. There were also no significant differences in the secondary outcomes.
CONCLUSIONS: The addition of IPACK to ACB and LIA did not provide any clinical analgesic benefits. Orthopedic surgeons and anesthesiologists are justified in using ACB and LIA without IPACK for TKA.
HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.
Opioid receptor agonists are often used when cancer patients undergo surgery or analgesic treatment. As analgesics in clinical care, opioids can provide intraoperative or to chronic cancer pain relief. Immune function plays an important role in anti-cancer therapy, with cellular immunity, comprised principally of T-lymphocytes and natural killer cells, representing the primary anti-cancer immune response. However, it remains unclear whether immune function is further affected with the use of opioids in already immunocompromised cancer patients. This article provides a review of the effects of commonly used clinical opioids, including morphine, oxycodone, fentanyl and tramadol, on immune function in cancer patients. It provides a summary of current evidence regarding the immunomodulatory effects of opioids in the cancer setting and mechanisms underlying these interactions.
Gastric ulcer and gastrorrhagia are recurrent chronic diseases hard to cure. After more than twenty years of clinical research and verification, mild, viscous and astringent Callicarpa bodinieri, Bletilla striata, hairyvein agrimony, pearl, panax notoginseng, elephant skin, Ilex rotunda Thunb, Cirsium japonicum, oriental arborvitae, donkey-hide gelatin and other traditional Chinese medicines with the efficacy of clearing heat and nourishing yin, cooling blood, dispelling blood stasis and diminishing swelling, and mainly for promoting granulation and stopping bleeding are selected to treat gastric and duodenal bulbar ulcer gastrorrhagia, and achieve a unique therapeutic effect. The drug is applied since 1992 up to now and cures countless patients, and no relapse occurs to the patients. Application of the formula has no need for treatment based on syndrome differentiation, and ''as long as the evidence of use the drug exists, the drug is applicable without the need to know all''. The hemostatic and granulation promoting powder provided by the invention has the characteristics of simplicity and convenience, safety and quick effect, thoroughness and no relapse, can restore the ulcer surface while treating gastrorrhagia. The powder is taken by mixing it with boiled water once a day, three times of medication can cure gastrorrhagia, and 7-10 times of medication can cure gastric ulcer. The purpose of radical treatment can be reached without herb decoction, fasting and venous transfusion. The powder provided by the invention fills the blank of treatment of gastric ulcer and gastrorrhagia by traditional Chinese medicine, and is a landmark initiative.
The invention belongs to the technical field of medicine, and concretely relates to a traditional Chinese medicine composition treating qi-blood deficiency type diabetes limb early-stage arteriosclerosis obliterans symptom. The traditional Chinese medicine is composed of the following traditional Chinese medicine ingredients in parts by weight: 4-8 parts of annular holostemma, 4-8 parts of incaruillea younghusbandii Sprague., 5-13 parts of root of broadleaf sedge, 11-19 parts of ficus erecta Thumb.var.beecheyana (Hook.et Arn.) King, 5-13 parts of aalia melanocarpa (Levl.)Lauener, 5-13 parts of mucuna birdwoodiana Tutch., 6-14 parts of rubia yunnanensis, 5-13 parts of disporopsis longifolia Craib, 6-14 parts of scrophularia henryi Hemsl., 4-8 parts of oxhide glue, 6-14 parts of rugosa paraphlomis, 5-13 parts of alyxia sinensis Champ.ex Benth., 4-8 parts of phlegmariurus hamiltonii (Spreng.) Love et Love var.petiolatus(Clarke)Ching, 5-13 parts of root of undulateleaf aralia, 5-13 parts of hypericum monanthemum Hook.f.et Thoms.ex Dver, 4-8 parts of micromelum root, 6-14 parts of pericarp of common sterculia, 4-8 parts of radix glycyrrhizae. The above traditional Chinese medicine ingredients are cooperated and together give play to effects of tonifying qi and blood, nourishing yin and moistening dryness, activating blood and freeing the collateral vessels, and the traditional Chinese medicine composition is capable of resisting platelet aggregation, improving blood viscosity, dilating blood vessels, increasing blood flow speed, and improving clinic symptoms and lower limb blood circulation.
Provided herein is a method for controlling a rate of fatty acid oxidation in mesenchymal cells, comprising modulating the expression or activity of ADCY5. The rate of fatty acid oxidation may be decreased by reducing the expression or activity of ADCY5. The rate of fatty acid oxidation may be increased by increasing the expression or activity of ADCY5. In some embodiments, the mesenchymal cell may be a mesenchymal stem cell, an adipocyte, an osteoblast, a chondrocyte, or a myocyte. In some embodiments, controlling the rate of fatty acid oxidation in mesenchymal stem cells comprises inhibiting fatty acid oxidation. In some embodiments, inhibiting fatty acid oxidation prevents development of Type 2 Diabetes (T2D). In some embodiments, controlling the rate of fatty acid oxidation in mesenchymal stem cells may comprise increasing the rate of fatty acid oxidation. Increasing the rate of fatty acid oxidation may promote bone formation.
Winged scapula is a rare musculoskeletal condition with numerous etiologies including spinal accessory nerve (SAN) palsy. Sport activities are rarely implicated with few scattered case reports. We report a case of an 18-year-old bodybuilder who suffered SAN palsy secondary to weightlifting exercises. Physical examination revealed winged scapula with painful mobility of the shoulder. A scapular magnetic resonance imaging scan and electromyography of the trapezius muscle were performed and confirmed the diagnosis of SAN palsy. Through this case, we review the literature of common and rare causes of SAN palsy and outline accepted treatment options.
The working conditions of prison officers are very stressful. Today, it is known that stress affects the health status of individuals in many ways. In this study, it was aimed to evaluate the musculoskeletal system problems, fatigue severity, depression levels, and quality of life of prison officers and to examine the relationship between these parameters and the socio-demographic characteristics of the participants.The study included a total of 141 volunteers. The prison management allowed the collection of data online due to the COVID-19 pandemic.141 prison officers between the ages of 18 and 65, working in Mula E Type Closed Penitentiary Institution, having completed at least one year in the profession and volunteering to participate in the study, participated in the research. Individuals who had received physical therapy in the last three months, had undergone surgery for an orthopedic reason in the last year, and had used pain medication for the last 15 days were not included in the study. The musculoskeletal problems of the participants were evaluated with the Cornell Musculoskeletal Disorders Questionnaire, fatigue levels were evaluated with the Fatigue Severity Scale, depression levels were evaluated with the Beck Depression Inventory, and quality of life was evaluated with the Nottingham Health Profile.

The Cornell Musculoskeletal Disorders Questionnaire consists of Likert-type questions inquiring about the painful region, the severity of pain, and the level of impact on work life for an individual. A total of 12 regions, starting from the neck area to the foot area, are examined. Each body region is scored on a scale ranging from 0 to 90. The Fatigue Severity Scale consists of 9 questions, with the lowest score being 9 and the highest score being 63. If the average of the scores obtained from these 9 questions is above 4, it indicates pathological fatigue. Participants were asked to consider the time from going to bed to falling asleep, the frequency of waking up after falling asleep, and the total time spent asleep. The Beck Depression Inventory consists of 21 questions, each scored between 0 and 3. The scores obtained from the scale are categorized into four groups. In the classification of the severity of depression, up to 9 points are considered no depression, 10-16 points are considered mild, 17-29 points are considered moderate, and 30-63 points are considered severe depression. The cutoff score for depression is accepted as 17.
This study assesses the efficacy of bilateral mesh sacrospinous ligament suspension (MSSLS) compared to laparoscopic sacrocolpopexy (LSC) in patients with uterine prolapse. Ninety-eight patients with uterine prolapse were evaluated at our hospital from January 2021 to January 2023. Patients were equally divided into two groups: the study group (undergoing MSSLS) and the control group (undergoing LSC) using a random number table. Various parameters including operation time, bleeding volume, indwelling catheter time, exhaust time, hospital stay, pelvic organ prolapse stage, postoperative recurrence rate, pain severity, quality of life, pelvic floor function, impact on sexual life, complications, and recurrence rate were recorded. The study group showed significant reductions in operation time, bleeding volume, indwelling catheter time, exhaust time, and hospital stay compared to the control group (P < 0.05). There were no significant differences in Aa, Ba, Ap, Bp, and C between the two groups before surgery (P > 0.05), but six months postoperatively, these indexes were significantly lower in the study group (P < 0.05). Pain severity did not differ significantly between the two groups before surgery (P > 0.05), but was significantly lower in the study group six months postoperatively (P < 0.05). Quality of life, pelvic floor function, and sexual life quality did not significantly differ before surgery, at 6 months, and at 12 months postoperatively (P > 0.05). All patients were followed up for 12-14 months, with an average follow-up time of (13.02 ± 1.36) months. The incidence of complications was significantly lower in the study group (P < 0.05), but there were no recurrences in either group, thus the difference was not statistically significant (P > 0.05). MSSLS emerges as a safe and efficacious treatment for uterine prolapse, notably reducing both complications and recurrence rates, rendering it suitable for broad clinical application.
Rheumatoid arthritis (RA) is classified as a persistent inflammatory autoimmune disorder leading to the subsequent erosion of articular cartilage and bone tissue originating from the synovium. The fundamental objective of therapeutic interventions in RA has been the suppression of inflammation. Nevertheless, conventional medicines that lack target specificity may exhibit unpredictable effects on cell metabolism. In recent times, there has been evidence suggesting that specialized pro-resolving mediators (SPMs), which are lipid metabolites, have a role in facilitating the resolution of inflammation and the reestablishment of tissue homeostasis. SPMs are synthesized by immune cells through the enzymatic conversion of omega-3 fatty acids. In the context of RA, there is a possibility of dysregulation in the production of these SPMs. In this review, we delve into the present comprehension of the endogenous functions of SPMs in RA as lipids that exhibit pro-resolutive, protective, and immunoresolvent properties.
### Drug Interactions with Other CNS Depressants

The concomitant use of other central nervous system depressants including sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers and alcohol may produce additive depressant effects. Respiratory depression, hypotension and profound sedation or coma may occur. When such combined therapy is contemplated, the dose of one or both agents should be reduced. Hydromorphone hydrochloride tablets should not be taken with alcohol. Opioid analgesics, including hydromorphone hydrochloride tablets, may enhance the action of neuromuscular blocking agents and produce an excessive degree of respiratory depression.

### Interactions with Mixed Agonist/Antagonist Opioid Analgesics

Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, and buprenorphine) should be administered with caution to a patient who has received or is receiving a course of therapy with a pure opioid agonist analgesic such as hydromorphone. In this situation, mixed agonist/antagonist analgesics may reduce the analgesic effect of hydromorphone and/or may precipitate withdrawal symptoms in these patients.
The invention relates to a Chinese traditional medicine for treating myopia and a preparation method and a use method thereof, which is invented for solving the problems of difficult myopia treatment and the like in the prior art. The Chinese traditional medicine for treating myopia is prepared from 29 raw material medicines containing 10g of borneol, 10g of safflower, 2g of antler, 6g of honey-fried licorice root, 15g of radix astragali, 20g of radix codonopsitis and the like. The preparation method of the Chinese traditional medicine for treating myopia comprises the following steps: decocting the raw material medicines into medicine soup; soaking cowherb seeds into the medicine soup for 72 hours, and drying the soaked cowherb seeds in the shade to obtain finished medicine beads. When in use, the finished medicine beads are placed at ear acupoints of a patient for 1-48 hours. The Chinese traditional medicine can adjust the visceral qi-blood circulation of the patient, promote blood circulation, improve a providing system for eye development from a source, and achieve the purposes of searching for roots and treating both principal and secondary aspects of diseases. The invention adopts an ear acupoint purely natural therapy without taking medicines or injections, has no side effect and is safe, reliable, convenient and easy in operation.
In late December 2019, several local health facilities reported clusters of patients with pneumonia of unknown cause that were epidemiologically linked to a seafood and wet animal wholesale market in Wuhan, Hubei Province, China. It is now confirmed that the etiology of this outbreak is a novel coronavirus, namely, 2019-nCoV. Of critical importance is rapid and simple diagnostic method to be used in clinical settings to timely inform and refine strategies that can prevent, control, and stop the spread of 2019-nCoV. Recombinase aided amplification (RAA) assay is a novel isothermal nucleic acid amplification technique in recent years, which has a variety of the advantages including high specificity and sensitivity, rapid detection (30 min), low cost, low equipment requirements and simple operation. The investigators has successfully detected a variety of pathogens using this technique. To develop a RAA assay for 2019-nCoV with the advantages of high speed, simple operation and low cost, and overcomes the shortcomings of the existing molecular detection methods. The investigators established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, The investigators also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Patients who were suspected of being infected with 2019-nCoV in the hospital.
Subjects may opt to enroll in this treatment sub-study involving melatonin treatment (0.1 - 3 mg, daily) for up to 1 year, with a minimum of 6 weeks. Throughout treatment, subjects will continue their saliva, plasma, and/or urine sampling to test for treatment efficacy.